We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Assay Detects Fish Trematode DNA in Human Stools

By LabMedica International staff writers
Posted on 13 Jul 2017
Amphimeriasis is a fish-borne disease caused by the liver fluke Amphimerus spp. More...
that has recently been reported as endemic in the tropical Pacific side of Ecuador with a high prevalence in humans and domestic animals.

The diagnosis of Amphimeriasis is based on the stool examination to identify parasite eggs, but it lacks sensitivity. Additionally, the morphology of the eggs may be confounded with other liver and intestinal flukes and no immunological or molecular methods have been developed to date.

Scientists at the Universidad Central del Ecuador (Quito, Ecuador) and their colleagues obtained human stool samples from indigenous communities during February 2016. The samples were processed for parasitological screening under light microscopy by direct examination, simple sedimentation, formalin-ether concentration and Kato-Katz techniques. After parasitological screening, a total of 44 stool samples were selected, including 25 (56.81%) that were positive for Amphimerus sp. eggs-by one or more parasitological methods-and 19 (43.18%) negative samples.

DNA extraction was performed using the Mini Stool DNA Extraction kit. To determine the specificity of polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP) assays to amplify only Amphimerus sp. DNA, a total of 16 DNA samples from several helminths, including trematodes, cestodes, nematodes and protozoa were used. DNA was measured using a Nanodrop ND-100 spectrophotometer. The LAMP assay was called LAMPhimerus.

The team obtained from the total of 25 parasitologically positive stool samples, 9/25 (36%) and 18/25 (72%) positive results when they applied LAMPhimerus for 60 min and 120 min, respectively. Additionally, positive results included 5/19 (26.3%) samples that were negative in all previously applied parasitological tests. Of the 11 that were simultaneously positive on three parasitological tests 82% were also positive on the LAMP assay; only the two samples, with the same very low egg count, were negative on the LAMP assay.

The authors have developed, for the first time, a LAMP assay (namely, LAMPhimerus) for the sensitive and specific detection of Amphimerus sp. DNA in human stool samples. After further studies for validation, the method could be readily adapted for effective field diagnosis and disease surveillance in amphimeriasis-endemic areas. The study was published on June 19, 2017, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Universidad Central del Ecuador


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.